Abstract:Background Epithelial-to-mesenchymal transition (EMT) and cancer stem cell (CSC) formation are key underlying causes that promote extensive metastasis, drug resistance, and tumor recurrence in highly lethal pancreatic cancer. The mechanisms leading to EMT and CSC phenotypes are not fully understood, which has hindered the development of effective targeted therapies capable of improving treatment outcomes in patients with pancreatic cancer. Results We show a central role of Aurora kinase A (AURKA) in promoting EMT and CSC phenotypes via ALDH1A1, which was discovered as its direct substrate using an innovative chemical genetic screen. AURKA phosphorylates ALDH1A1 at three critical residues which exert a multifaceted regulation over its level, enzymatic activity, and quaternary structure. While all three phosphorylation sites contribute to its increased stability, T267 phosphorylation primarily regulates ALDH1A1 activity. AURKA-mediated phosphorylation rapidly dissociates tetrameric ALDH1A1 into a highly active monomeric species. ALDH1A1 also reciprocates and prevents AURKA degradation, thereby triggering a positive feedback activation loop which drives highly aggressive phenotypes in cancer. Phospho-resistant ALDH1A1 fully reverses EMT and CSC phenotypes, thus serving as dominant negative, which underscores the clinical significance of the AURKA-ALDH1A1 signaling axis in pancreatic cancer. Conclusions While increased levels and activity of ALDH1A1 are hallmarks of CSCs, the underlying molecular mechanism remains unclear. We show the first phosphorylation-dependent regulation of ALDH1A1, which increases its levels and activity via AURKA. Recent global phospho-proteomic screens have revealed increased phosphorylation of ALDH1A1 at the T267 site in human cancers and healthy liver tissues where ALDH1A1 is highly expressed and active, indicating that this regulation is likely crucial both in normal and diseased states. This is also the first study to demonstrate oligomer-dependent activity of ALDH1A1, signifying that targeting its oligomerization state may be an effective therapeutic approach for counteracting its protective functions in cancer. Finally, while AURKA inhibition provides a potent tool to reduce ALDH1A1 levels and activity, the reciprocal loop between them ensures that their concurrent inhibition will be highly synergistic when inhibiting tumorigenesis, chemoresistance, and metastasis in highly aggressive pancreatic cancer and beyond.

The significant others of aurora kinase a in cancer: combination is the key

Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy

Aurora‐A Kinase: A Potent Oncogene and Target for Cancer Therapy

A comprehensive review on role of Aurora kinase inhibitors (AKIs) in cancer therapeutics

Revisiting Aurora Kinase B: A Promising Therapeutic Target for Cancer Therapy.

The role of Aurora kinase A in hepatocellular carcinoma: Unveiling the intriguing functions of a key but still underexplored factor in liver cancer

Pan-cancer analysis and in vitro validation of the oncogenic and prognostic roles of AURKA in human cancers

Aurora A Is Essential for Early Embryonic Development and Tumor Suppression

Research progress on the relationship between AURKA and tumorigenesis: the neglected nuclear function of AURKA

Aurora Kinases As Targets for Cancer Therapy.

Breaking the 'undruggable' barrier: Revealing molecular mechanisms in Aurora Kinase A/Myc protein interplay targeting cancers

Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells

Phosphorylation-dependent Regulation of ALDH1A1 by Aurora Kinase A: Insights on Their Synergistic Relationship in Pancreatic Cancer

Emerging roles of Aurora-A kinase in cancer therapy resistance

Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to Its Aggressive Behavior

Aurora Kinase a Promotes the Progression of Papillary Thyroid Carcinoma by Activating the Mtorc2-Akt Signalling Pathway

Aurora Kinase A Inhibition Potentiates Platinum and Radiation Cytotoxicity in Non-Small-Cell Lung Cancer Cells and Induces Expression of Alternative Immune Checkpoints

Aurora A Kinase and Gynecological Tumors

Post-transcriptional control drives Aurora kinase A expression in human cancers

AURKA Promotes Renal Cell Carcinoma Progression Via Regulation of CCNB1 Transcription

Therapeutic Rationale to Target Highly Expressed Aurora Kinase A Conferring Poor Prognosis in Cholangiocarcinoma